| __timestamp | Blueprint Medicines Corporation | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 31844000 | 21226345 |
| Thursday, January 1, 2015 | 48588000 | 87718074 |
| Friday, January 1, 2016 | 81131000 | 93831530 |
| Sunday, January 1, 2017 | 144687000 | 79419009 |
| Monday, January 1, 2018 | 243621000 | 132166913 |
| Tuesday, January 1, 2019 | 331450000 | 89124838 |
| Wednesday, January 1, 2020 | 326860000 | 65782137 |
| Friday, January 1, 2021 | 601033000 | 88845513 |
| Saturday, January 1, 2022 | 477419000 | 134715000 |
| Sunday, January 1, 2023 | 427720000 | 180142000 |
| Monday, January 1, 2024 | 341433000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Blueprint Medicines Corporation and Intra-Cellular Therapies, Inc. have demonstrated distinct strategies in their R&D investments. From 2014 to 2023, Blueprint Medicines has consistently outpaced Intra-Cellular Therapies, with R&D expenses peaking at nearly 600% higher in 2021 compared to 2014. In contrast, Intra-Cellular Therapies has shown a steady increase, with a notable 750% rise in R&D spending from 2014 to 2023. This divergence highlights Blueprint's aggressive pursuit of breakthroughs, while Intra-Cellular focuses on sustainable growth. As the biotech landscape evolves, these strategic choices will shape their future trajectories, offering valuable insights into the dynamics of innovation-driven industries.
R&D Spending Showdown: Gilead Sciences, Inc. vs Blueprint Medicines Corporation
Research and Development Investment: Zoetis Inc. vs Intra-Cellular Therapies, Inc.
Research and Development Expenses Breakdown: argenx SE vs Intra-Cellular Therapies, Inc.
Alnylam Pharmaceuticals, Inc. vs Blueprint Medicines Corporation: Strategic Focus on R&D Spending
Research and Development Investment: Genmab A/S vs Intra-Cellular Therapies, Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Opthea Limited
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Apellis Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or Celldex Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Dr. Reddy's Laboratories Limited and Blueprint Medicines Corporation
Research and Development: Comparing Key Metrics for Blueprint Medicines Corporation and ImmunityBio, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Blueprint Medicines Corporation and Mesoblast Limited